-
公开(公告)号：US20150157691A1
公开(公告)日：2015-06-11
申请号：US14561981
申请日：2014-12-05
Applicant: Texas Tech University System
Inventor： Maurizio Chiriva-Internati , Jose A. Figueroa , Everardo Cobos
IPC: A61K38/17 , G01N33/561 , A61K31/337
CPC classification number: A61K38/1732 , A61K31/337 , A61K48/00 , C07K14/4726 , G01N33/57449 , G01N2500/10 , A61K2300/00
Abstract: The present invention includes a method for the treatment of an advanced ovarian cancer, comprising: identifying a patient with advanced ovarian cancer; and administering to the patient an effective amount of truncated, dominant negative form of Galectin-3 sufficient to reduce the advanced ovarian cancer. In certain aspects, the truncated, dominant negative form of Galectin-3 is provided in an amount sufficient to reduce at least one of growth, motility, invasion, angiogenesis, or prevents Akt/NF-κB activation of the ovarian cancer.
Abstract translation: 本发明包括一种治疗晚期卵巢癌的方法，包括：鉴定晚期卵巢癌患者; 并向患者施用足够减少晚期卵巢癌的有效量的截短的，显性阴性形式的Galectin-3。 在某些方面，提供半数优势阴性形式的半乳凝素-3以足以减少生长，运动性，侵袭，血管发生或抑制卵巢癌的Akt / NF-κB活化中的至少一种的量。
-
2.发明申请GALECTIN-3 INHIBITOR (GAL-3M) IS ASSOCIATED WITH ADDITIVE ANTI-MYELOMA AND ANTI-SOLID TUMOR EFFECTS, DECREASED OSTEOCLASTOGENESIS AND ORGAN PROTECTION WHEN USED IN COMBINATION WITH PROTEASOME INHIBITORS 审中-公开GALECTIN-3抑制剂（GAL-3M）与添加抗血清和抗固体肿瘤效应有关，当与抗抑郁药组合使用时，减少了OSTEOCLASTOGENESISISIS和ORGAN保护公开(公告)号：US20150216931A1
公开(公告)日：2015-08-06
申请号：US14612757
申请日：2015-02-03
Applicant: Texas Tech University System
Inventor： Maurizio Chiriva-Internati , Jose A. Figueroa , Everardo Cobos
CPC classification number: C07K14/4726 , A61K31/145 , A61K31/27 , A61K31/336 , A61K31/353 , A61K31/4015 , A61K31/407 , A61K31/427 , A61K31/5377 , A61K31/69 , A61K31/713 , A61K38/05 , A61K38/06 , A61K38/07 , A61K38/1732 , A61K45/06 , G01N33/5011 , A61K2300/00 , A61K31/365
Abstract: The present invention includes a method for the treatment of myeloma comprising identifying a patient with myeloma and administering to the patient a synergistic, effective amount of a truncated, dominant negative form of Galectin-3 and a proteasome inhibitor.
Abstract translation: 本发明包括用于治疗骨髓瘤的方法，其包括鉴定患有骨髓瘤的患者，并向患者施用协同的有效量的半衰期，显性失活形式的Galectin-3和蛋白酶体抑制剂。
-
3.发明申请Galectin-3 Inhibitor (Gal-3M) is Associated with Additive Anti-Myeloma and Anti-Solid Tumor Effects, Decreased Osteoclastogenesis and Organ Protection when Used in Combination with Proteasome Inhibitors 审中-公开Galectin-3抑制剂（Gal-3M）与添加抗骨髓瘤和抗固体肿瘤作用相关联，当与蛋白酶体抑制剂组合使用时，破骨细胞形成和器官保护减少公开(公告)号：US20160122408A1
公开(公告)日：2016-05-05
申请号：US14992334
申请日：2016-01-11
Applicant: Texas Tech University System
Inventor： Maurizio Chiriva-Internati , Jose A. Figueroa , Everardo Cobos
IPC: C07K14/47
CPC classification number: C07K14/4726 , A61K31/145 , A61K31/27 , A61K31/336 , A61K31/353 , A61K31/4015 , A61K31/407 , A61K31/427 , A61K31/5377 , A61K31/69 , A61K31/713 , A61K38/05 , A61K38/06 , A61K38/07 , A61K38/1732 , A61K45/06 , G01N33/5011 , A61K2300/00 , A61K31/365
Abstract: The present invention includes a method for the treatment of myeloma comprising identifying a patient with myeloma and administering to the patient a synergistic, effective amount of a truncated, dominant negative form of Gaicctin-3 and a proteasome inhibitor.
Abstract translation: 本发明包括用于治疗骨髓瘤的方法，包括鉴定患有骨髓瘤的患者，并向患者施用协同的有效量的截短，显性失活形式的Gaicctin-3和蛋白酶体抑制剂。
-
4.发明申请Galectin-3 Inhibitor (Gal-3M) is Associated with Additive Anti-Myeloma and Anti-Solid Tumor Effects, Decreased Osteoclastogenesis and Organ Protection when Used in Combination with Proteasome Inhibitors 审中-公开Galectin-3抑制剂（Gal-3M）与添加抗骨髓瘤和抗固体肿瘤作用相关联，当与蛋白酶体抑制剂组合使用时，破骨细胞形成和器官保护减少公开(公告)号：US20160122407A1
公开(公告)日：2016-05-05
申请号：US14992173
申请日：2016-01-11
Applicant: Texas Tech University System
Inventor： Maurizio Chiriva-Internati , Jose A. Figueroa , Everardo Cobos
IPC: C07K14/47
CPC classification number: C07K14/4726 , A61K31/145 , A61K31/27 , A61K31/336 , A61K31/353 , A61K31/4015 , A61K31/407 , A61K31/427 , A61K31/5377 , A61K31/69 , A61K31/713 , A61K38/05 , A61K38/06 , A61K38/07 , A61K38/1732 , A61K45/06 , G01N33/5011 , A61K2300/00 , A61K31/365
Abstract: The present invention includes a method for the treatment of myeloma comprising identifying a patient with myeloma and administering to the patient a synergistic, effective amount of a truncated, dominant negative form of Galectin-3 and a proteasome inhibitor.
Abstract translation: 本发明包括用于治疗骨髓瘤的方法，包括鉴定患有骨髓瘤的患者，并向患者施用协同的有效量的半衰期，显性失活形式的Galectin-3和蛋白酶体抑制剂。
-
-
-
Search Results
4
records
(took 0.015 seconds)
